Clinical trial · Observational
Myeloproliferative Neoplasms and Bone Structure
NCT01816022CI-TRIAL-00009786unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a clinical study to evaluate the effect of CMPN (Chronic myeloproliferative neoplasm) to the bone. The hypothesis is that patients with CMPN have a higher fracture-rate compared to the background population. We expect to find a lower BMD using conventional DXA scan (dual energy x-ray absorptiometry), and a change in other parameters using HR-pQCT (high-resolution peripheral quantitative computerized tomography).Biochemical bone markers is measured to support the hypothesis.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
| Primary Myelofibrosis | Primary Myelofibrosis | ONTOLOGY_EXACT | 0.98 |
| Thrombocythemia, Essential | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Bone Mineral Density (BMD)
- timeFrame
- 1 day
- description
- Patients will undergo one DXA scan independent of time of CMPN diagnosis
Secondary outcomes (1)
- measure
- Evaluation of Geometry, Strength and Micro-Structure of the bone.
- timeFrame
- 1 day
- description
- Patients will undergo one HR.pQCT indepedent of the time of the diagnosis of CMPN
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of PV (according to WHO 2008 criteria), only JAK2-pos.(Janus kinase 2) * Diagnosis of ET (according to WHO 2008 criteria), only JAK2-pos. * Diagnosis of PMF (according to WHO 2008 criteria)independent of JAK2-status. Exclusion Criteria: * Pregnancy * Bone Diseases (Mb. Pagets, Myelomatosis, MGUS (monoclonal gammopathy of undetermined significance), osteogenesis imperfecta, Prim. hyperparathyroidism, osteomalacia. * Drugs (Prednisone\>3 mth, anti-osteoporotic drugs, anti-estrogen drugs. * Presence of any psychologic condition or language barrier, which may interfere which a complete understanding, and arise ethnical considerations.
References
Publications (1)
- DERIVEDFarmer S, Vestergaard H, Hansen S, Shanbhogue VV, Stahlberg CI, Hermann AP, Frederiksen H. Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers. Int J Hematol. 2015 Jul;102(1):67-75. doi: 10.1007/s12185-015-1803-3. Epub 2015 May 5. PMID 25939704